Results 21 to 30 of about 328,615 (242)

Effects of combined diethylcarbamazine and albendazole treatment of bancroftian filariasis on parasite uptake and development in Culex pipiens L. [PDF]

, 2005
Farid, Hoda A, Hammad, Ragaa E, Hassan, Marah M, Ramzy, Reda M.R,, Setouhy, Maged El, Weil, Gary J   +5 more
core   +4 more sources

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study [PDF]

, 2019
BackgroundThe Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to hundreds of millions of people annually to treat filarial infections and prevent elephantiasis.
Bogus, Joshua, DOLF IDA Safety Study Group,, et al.,, Fischer, Peter U, Goss, Charles W, O\u27Brian, K., Schechtman, Kenneth B, Weil, Gary J   +7 more
core   +6 more sources

Diethylcarbamazine increases activation of voltage-activated potassium (SLO-1) currents in Ascaris suum and potentiates effects of emodepside. [PDF]

PLoS Neglected Tropical Diseases, 2014
Diethylcarbamazine is a drug that is used for the treatment of filariasis in humans and animals; it also has effects on intestinal nematodes, but its mechanism of action remains unclear.
Samuel K Buxton, Alan P Robertson, Richard J Martin   +2 more
doaj   +1 more source

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d\u27Ivoire [PDF]

, 2019
BackgroundA single co-administered dose of ivermectin (IVM) plus diethylcarbamazine (DEC) plus albendazole (ALB), or triple-drug therapy, was recently found to be more effective for clearing microfilariae (Mf) than standard DEC plus ALB currently used ...
Bjerum, Catherine M, Chhonker, Yashpal S, Edi, Constant, King, Christopher L, Koudou, Benjamin G, Meite, Aboulaye, Murry, Daryl J, Ouattara, Allassane F, Penali, Louis K, Weil, Gary J   +9 more
core   +4 more sources

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach [PDF]

, 2019
BACKGROUND: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs.
Dubray, Christine, Fischer, Peter U, Goss, Charles W, Hardy, Myra, Jambulingam, Purushothaman, King, Christopher L, Laman, Moses, Lemoine, Jean Frantz, O\u27Brian, Katiuscia, Robinson, Leanne J, Samuela, Josaia, Schechtman, Kenneth B, Subramanian, Swaminathan, Supali, Taniawati, Weil, Gary J   +14 more
core   +2 more sources

Mass drug administration coverage evaluation survey for lymphatic Filariasis in Bagalkot and Gulbarga districts

Indian Journal of Community Medicine, 2012
Background: Lymphatic filariasis (LF) is endemic in 83 countries and territories, with more than a billion people at risk of infection. In view with the global elimination, mass drug administration (MDA) with single dose of diethylcarbamazine and ...
Prakash Kurubarahalli Patel
doaj   +1 more source

Lymphatic Filariasis Control in Tanzania: Effect of Six Rounds of Mass Drug Administration with Ivermectin and Albendazole on Infection and Transmission. [PDF]

, 2013
Control of lymphatic filariasis (LF) in most countries of sub-Saharan Africa is based on annual mass drug administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission. We present findings from a detailed study
C Chaccour, DJ Tisch, DW Meyrowitsch, DW Meyrowitsch, DW Meyrowitsch, E Michael, E Michael, E Michael, EM Pedersen, Erling M Pedersen, FO Richards, GJ Weil, GJ Weil, GJ Weil, H Joseph, HM Joseph, JD King, JE McMahon, JE McMahon, JL Liang, JM Mlandonicky, KC Kobylinski, KD Ramaiah, KY Won, LM Zeldenryk, M Parker, MN Malecela, Mwele N Malecela, N Kolstrup, O Mitja, Paul E Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PE Simonsen, PJ Hotez, RMR Ramzy, RT Rwegoshora, Stephen M Magesa, WHO, WHO, William N Kisinza, YA Derua, Yahya A Derua   +48 more
core   +1 more source

Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study. [PDF]

PLoS Neglected Tropical Diseases, 2018
BACKGROUND:Loa loa infection is endemic in limited areas of West-Central Africa. Loiasis has been associated with excess mortality, but clinical studies on its treatment are scant, particularly outside endemic areas, due to the rarity of cases diagnosed.
Federico Gobbi, Emmanuel Bottieau, Olivier Bouchaud, Dora Buonfrate, Fernando Salvador, Gerardo Rojo-Marcos, Paola Rodari, Jan Clerinx, Begoña Treviño, Juan Paulo Herrera-Ávila, Andreas Neumayr, Guido Calleri, Andrea Angheben, Camilla Rothe, Lorenzo Zammarchi, Massimo Guerriero, Zeno Bisoffi   +16 more
doaj   +1 more source

Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy

Emerging Infectious Diseases, 2019
We describe the outcomes of 16 cases of imported loiasis in Italy. Patients had microfilaremia
Federico Gobbi, Dora Buonfrate, Francesca Tamarozzi, Monica Degani, Andrea Angheben, Zeno Bisoffi   +5 more
doaj   +1 more source

Genital filariasis presenting as a vaginal wall cystic lesion

IDCases, 2020
Vaginal cystic lesions are rare incidental findings detected during physical examination and imaging. To our knowledge, filariasis as a cause of vaginal cystic lesions has not been previously reported in the English literature.
Prasanna Ghimire, Pragya Gautam Ghimire
doaj   +1 more source